Loading stock data…
CDT Equity Inc. (CDT)
$0.62-0.01 (-1.33%)
Market ClosedLast close Sep 8
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CDT Equity Inc. in the Healthcare sector is trading at $0.62 with a market capitalization of $8M. The stock is currently near its 52-week low of $0.58, remaining 99.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 5 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 5) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.00M↑ | -$3.66M↑ | -$21.16M↓ | -$6.94M↓ | -$4.95M |
| Net Income | -$4.64M↓ | -$4.06M↑ | -$21.32M↓ | -$7.12M↓ | -$6.03M |
Peer Comparison
JNJUNHPFE
Fundamentals
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmun...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.45M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.03%
Volume
Today's trading volume
294,475
Recent News
CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. AstraZeneca PLC is among the best cancer stocks on this list. TheFly reported on May 6 that CDT Equity announced that AZD5904, a selective inhibitor of human myeloperoxidase originally licensed from AstraZeneca PLC (NYSE:AZN), has entered the Patent […]
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.5% and the S